IGC Pharma (IGC Pharma) Accounts Receivable : $0.09 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. IGC Pharma's accounts receivables for the quarter that ended in Dec. 2023 was $0.09 Mil.

Accounts receivable can be measured by Days Sales Outstanding. IGC Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 41.15.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. IGC Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.00.

IGC Pharma Accounts Receivable Historical Data

The historical data trend for IGC Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Accounts Receivable Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Accounts Receivable

Get a 7-Day Free Trial

0.08

0.13

0.18

0.13

0.11

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															0.25	0.11	0.23	0.14	0.09

IGC Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

IGC Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

IGC Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.092	/	0.204	*	91
=	41.15

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), IGC Pharma's accounts receivable are only considered to be worth 75% of book value:

IGC Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.378	+	0.75 * 0.092	+	0.5 * 1.925	-	2.206
-	0	-	0)	/	63.7344
=	0.00

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

IGC Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (IGC Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

IGS1:Germany

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Executives

James P Moran	director	914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch	director	14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins	director
Ram Mukunda	director, officer: Exec. Chairman & CEO
Claudia Grimaldi	officer: Vice president and PFO	PO BOX 60642, POTOMAC MD 20859
Rohit Goel	officer: Manager & PAO	PO BOX 60642, POTOMAC MD 20859
John Cherin	officer: CFO, Treasurer and PAO	662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai	director, officer: Interim CFO	4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna	director	330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy	director	10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani	director	INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd.	10 percent owner	C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii	10 percent owner	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs	10 percent owner	600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd.	10 percent owner	C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305